Oporia Osteoporosis NDA Review Extended To September
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's review of Pfizer's selective estrogen receptor modulator Oporia (lasofoxifene) for the treatment of osteoporosis has been extended until September